Core Viewpoint - Catalyst Pharmaceutical (CPRX) shows potential for significant upside, with a mean price target of $34 indicating a 45.3% increase from the current price of $23.4 [1] Price Targets and Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $1.63, where the lowest estimate is $32.00 (36.8% increase) and the highest is $36.00 (53.9% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [9] Analyst Sentiment and Earnings Estimates - Analysts are optimistic about CPRX's earnings prospects, as indicated by a positive trend in earnings estimate revisions, with a 15.4% increase in the Zacks Consensus Estimate for the current year [11][12] - CPRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, and reliance solely on them may not yield favorable returns [3][7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - BrightSpring Health Services, Inc. (BTSG) shows potential for upside with a mean price target of $53.14, indicating a 25.5% increase from the current price of $42.33 [1] Price Targets and Analyst Consensus - The average price target consists of 14 estimates ranging from a low of $48.00 to a high of $60.00, with a standard deviation of $3.3, suggesting a consensus among analysts [2] - The lowest estimate indicates a 13.4% increase, while the highest suggests a 41.7% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about BTSG's earnings prospects, with a positive trend in earnings estimate revisions [11] - The Zacks Consensus Estimate for the current year has risen by 17.1% over the past month, with seven estimates increasing and no negative revisions [12] - BTSG holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are a common tool for investors, they can often mislead and should not be the sole basis for investment decisions [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Seanergy Maritime Holdings Corp (SHIP) has seen a 24.5% increase in share price over the past four weeks, closing at $13.28, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $16.63, representing a 25.2% upside [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $3.09, where the lowest estimate is $12.50 (5.9% decline) and the highest is $20.00 (50.6% increase) [2] - A low standard deviation indicates a strong agreement among analysts regarding the stock's price movement, suggesting a more reliable consensus [2][9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about SHIP's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 42.1% over the past month, with two estimates increasing and no negative revisions [12] - SHIP holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Conclusion on Price Movement - While the consensus price target may not be a definitive indicator of SHIP's potential gains, the implied direction of price movement appears to be a useful guide for investors [14]

Core Viewpoint - Insmed (INSM) shows potential for significant upside, with a mean price target of $215.1 indicating a 33.6% increase from the current price of $161 [1]. Price Targets - The average of 20 short-term price targets ranges from a low of $162.00 to a high of $241.00, with a standard deviation of $19.56, suggesting variability in analyst estimates [2]. - The lowest estimate indicates a 0.6% increase, while the highest suggests a 49.7% upside [2]. Analyst Consensus and Earnings Estimates - Analysts are optimistic about INSM's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlate with stock price movements [4][11]. - The Zacks Consensus Estimate for the current year has increased by 16.1% over the past month, with three estimates rising and one falling [12]. - INSM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]. Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be prudent, as analysts' ability to set unbiased targets has been questioned [3][10]. - Analysts often set optimistic price targets due to business incentives, which can lead to inflated estimates [8].

Core Viewpoint - Aldeyra Therapeutics, Inc. (ALDX) shows potential for significant upside, with a mean price target of $9 indicating a 79.3% increase from the current price of $5.02 [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $1.22, suggesting variability in analyst predictions [2] - The lowest price target of $7.00 indicates a 39.4% increase, while the highest target of $10.00 suggests a 99.2% increase [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about ALDX's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 19.4%, with one estimate moving higher and no negative revisions [12] - ALDX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' ability to set accurate targets has been questioned [3][7] - Price targets should be treated with skepticism, as they can often mislead investors [10]

分组1 - Janux Therapeutics, Inc. (JANX) shares have increased by 1.8% over the past four weeks, closing at $13.99, with a mean price target of $58.65 indicating a potential upside of 319.2% [1] - The mean estimate consists of 17 short-term price targets with a standard deviation of $34.53, where the lowest estimate is $12.00 (14.2% decline) and the highest is $150.00 (972.2% increase) [2] - Analysts show strong agreement on the company's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] 分组2 - The Zacks Consensus Estimate for the current year has risen by 0.2% over the past month, with one estimate increasing and no negative revisions [12] - JANX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - Forestar Group (FOR) has shown a 5% increase in stock price over the past four weeks, with a mean price target of $33 indicating a potential upside of 27.6% from the current price of $25.86 [1] Group 1: Price Targets and Analyst Consensus - The mean estimate for FOR includes four short-term price targets with a standard deviation of $5.1, suggesting variability in analyst predictions. The lowest estimate is $26.00 (0.5% increase), while the highest is $38.00 (47% increase) [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Group 2: Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about FOR's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 8.1%, with one estimate moving higher and no negative revisions [12] Group 3: Zacks Rank and Investment Implications - FOR currently holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside in the near term [13] - While the consensus price target may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14]

Core Viewpoint - National Vision (EYE) shares have increased by 1.8% over the past four weeks, closing at $26.4, with a mean price target of $33.18 indicating a potential upside of 25.7% according to Wall Street analysts [1] Price Targets and Analyst Estimates - The mean estimate consists of 11 short-term price targets with a standard deviation of $4.29, where the lowest estimate is $27.00 (2.3% increase) and the highest is $39.00 (47.7% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [2][9] Earnings Estimates and Market Sentiment - Analysts are optimistic about EYE's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 5%, with one estimate moving higher and no negative revisions [12] Zacks Rank and Investment Potential - EYE currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [14]

Core Viewpoint - Day One Biopharmaceuticals, Inc. (DAWN) has seen a 22.5% increase in share price over the past four weeks, closing at $10.73, with a mean price target of $22.25 indicating a potential upside of 107.4% according to Wall Street analysts [1]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $4.86, where the lowest estimate of $16.00 suggests a 49.1% increase, and the highest estimate of $29.00 indicates a potential surge of 170.3% [2]. - A low standard deviation signifies a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Optimism - Analysts are optimistic about DAWN's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11]. - The Zacks Consensus Estimate for the current year has increased by 20.6% over the past month, with one estimate rising and no negative revisions [12]. - DAWN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13]. Caution on Price Targets - While price targets are often sought after by investors, they can mislead and should not be the sole basis for investment decisions, as empirical research indicates that they rarely predict actual stock price movements [7][10].

Core Viewpoint - K12 (LRN) has shown a 6.4% increase in stock price over the past four weeks, with a mean price target of $105 indicating a potential upside of 49.2% from the current price of $70.38 [1] Price Targets - The average price target consists of four estimates ranging from a low of $75.00 to a high of $125.00, with a standard deviation of $24.49, suggesting variability in analyst predictions [2] - The lowest estimate indicates a 6.6% increase, while the highest suggests a 77.6% upside [2] Analyst Sentiment - Analysts show strong agreement regarding LRN's ability to report better earnings than previously predicted, which supports the potential for stock upside [4] - A positive trend in earnings estimate revisions has been correlated with stock price movements, indicating that analysts' optimism may be justified [11] Earnings Estimates - Over the last 30 days, one earnings estimate for LRN has increased, leading to a 1.1% rise in the Zacks Consensus Estimate [12] - LRN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]